Cargando…
Reversion of High-level Mecillinam Resistance to Susceptibility in Escherichia coli During Growth in Urine
Mecillinam (amdinocillin) is a β-lactam antibiotic used to treat uncomplicated urinary tract infections (UTIs). We have previously shown that inactivation of the Escherichia coli cysB gene is the major cause of mecillinam resistance (Mec(R)) in clinical isolates. In this study, we used different E....
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605379/ https://www.ncbi.nlm.nih.gov/pubmed/28855073 http://dx.doi.org/10.1016/j.ebiom.2017.08.021 |
_version_ | 1783264980142915584 |
---|---|
author | Thulin, Elisabeth Thulin, Måns Andersson, Dan I. |
author_facet | Thulin, Elisabeth Thulin, Måns Andersson, Dan I. |
author_sort | Thulin, Elisabeth |
collection | PubMed |
description | Mecillinam (amdinocillin) is a β-lactam antibiotic used to treat uncomplicated urinary tract infections (UTIs). We have previously shown that inactivation of the Escherichia coli cysB gene is the major cause of mecillinam resistance (Mec(R)) in clinical isolates. In this study, we used different E. coli strains (laboratory and clinical isolates) that were Mec(R) due to cysB mutations to determine how mecillinam susceptibility was affected during growth in urine compared to growth in the commonly used growth medium Mueller Hinton (MHB). We also examined mecillinam susceptibility when bacteria were grown in urine obtained from 48 different healthy volunteers. Metabolome analysis was done on the urine samples and the association between the mecillinam susceptibility patterns of the bacteria and urine metabolite levels was studied. Two major findings with clinical significance are reported. First, Mec(R)E. coli cysB mutant strains (both laboratory and clinical isolates) were always more susceptible to mecillinam when grown in urine as compared to laboratory medium, with many strains showing complete phenotypic susceptibility in urine. Second, the degree of reversion to susceptibility varied between urine samples obtained from different individuals. This difference was correlated with osmolality such that in urine with low osmolality the Mec(R) mutants were more susceptible to mecillinam than in urine with high osmolality. This is the first example describing conditional resistance where a genetically stable antibiotic resistance can be phenotypically reverted to susceptibility by metabolites present in urine. These findings have several important clinical implications regarding the use of mecillinam to treat UTIs. First, they suggest that mecillinam can be used to treat also those clinical strains that are identified as Mec(R) in standard laboratory tests. Second, the results suggest that testing of mecillinam susceptibility in the laboratory ought to be performed in media that mimics urine to obtain clinically relevant susceptibility testing results. Third, these findings imply that changes in patient behavior, such as increased water intake or use of diuretics to reduce urine osmolality and increased intake of cysteine, might induce antibiotic susceptibility in an infecting Mec(R)E. coli strain and thereby increase treatment efficiency. |
format | Online Article Text |
id | pubmed-5605379 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-56053792017-09-26 Reversion of High-level Mecillinam Resistance to Susceptibility in Escherichia coli During Growth in Urine Thulin, Elisabeth Thulin, Måns Andersson, Dan I. EBioMedicine Research Paper Mecillinam (amdinocillin) is a β-lactam antibiotic used to treat uncomplicated urinary tract infections (UTIs). We have previously shown that inactivation of the Escherichia coli cysB gene is the major cause of mecillinam resistance (Mec(R)) in clinical isolates. In this study, we used different E. coli strains (laboratory and clinical isolates) that were Mec(R) due to cysB mutations to determine how mecillinam susceptibility was affected during growth in urine compared to growth in the commonly used growth medium Mueller Hinton (MHB). We also examined mecillinam susceptibility when bacteria were grown in urine obtained from 48 different healthy volunteers. Metabolome analysis was done on the urine samples and the association between the mecillinam susceptibility patterns of the bacteria and urine metabolite levels was studied. Two major findings with clinical significance are reported. First, Mec(R)E. coli cysB mutant strains (both laboratory and clinical isolates) were always more susceptible to mecillinam when grown in urine as compared to laboratory medium, with many strains showing complete phenotypic susceptibility in urine. Second, the degree of reversion to susceptibility varied between urine samples obtained from different individuals. This difference was correlated with osmolality such that in urine with low osmolality the Mec(R) mutants were more susceptible to mecillinam than in urine with high osmolality. This is the first example describing conditional resistance where a genetically stable antibiotic resistance can be phenotypically reverted to susceptibility by metabolites present in urine. These findings have several important clinical implications regarding the use of mecillinam to treat UTIs. First, they suggest that mecillinam can be used to treat also those clinical strains that are identified as Mec(R) in standard laboratory tests. Second, the results suggest that testing of mecillinam susceptibility in the laboratory ought to be performed in media that mimics urine to obtain clinically relevant susceptibility testing results. Third, these findings imply that changes in patient behavior, such as increased water intake or use of diuretics to reduce urine osmolality and increased intake of cysteine, might induce antibiotic susceptibility in an infecting Mec(R)E. coli strain and thereby increase treatment efficiency. Elsevier 2017-08-24 /pmc/articles/PMC5605379/ /pubmed/28855073 http://dx.doi.org/10.1016/j.ebiom.2017.08.021 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research Paper Thulin, Elisabeth Thulin, Måns Andersson, Dan I. Reversion of High-level Mecillinam Resistance to Susceptibility in Escherichia coli During Growth in Urine |
title | Reversion of High-level Mecillinam Resistance to Susceptibility in Escherichia coli During Growth in Urine |
title_full | Reversion of High-level Mecillinam Resistance to Susceptibility in Escherichia coli During Growth in Urine |
title_fullStr | Reversion of High-level Mecillinam Resistance to Susceptibility in Escherichia coli During Growth in Urine |
title_full_unstemmed | Reversion of High-level Mecillinam Resistance to Susceptibility in Escherichia coli During Growth in Urine |
title_short | Reversion of High-level Mecillinam Resistance to Susceptibility in Escherichia coli During Growth in Urine |
title_sort | reversion of high-level mecillinam resistance to susceptibility in escherichia coli during growth in urine |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605379/ https://www.ncbi.nlm.nih.gov/pubmed/28855073 http://dx.doi.org/10.1016/j.ebiom.2017.08.021 |
work_keys_str_mv | AT thulinelisabeth reversionofhighlevelmecillinamresistancetosusceptibilityinescherichiacoliduringgrowthinurine AT thulinmans reversionofhighlevelmecillinamresistancetosusceptibilityinescherichiacoliduringgrowthinurine AT anderssondani reversionofhighlevelmecillinamresistancetosusceptibilityinescherichiacoliduringgrowthinurine |